Nexalin Technology (NXL) EBITDA (2021 - 2026)
Nexalin Technology has reported EBITDA over the past 5 years, most recently at -$2.4 million for Q4 2025.
- For Q4 2025, EBITDA rose 16.16% year-over-year to -$2.4 million; the TTM value through Dec 2025 reached -$8.2 million, down 8.07%, while the annual FY2025 figure was -$8.2 million, 8.07% down from the prior year.
- EBITDA for Q4 2025 was -$2.4 million at Nexalin Technology, down from -$2.3 million in the prior quarter.
- Over five years, EBITDA peaked at -$135401.0 in Q3 2022 and troughed at -$2.8 million in Q4 2024.
- A 5-year average of -$1.4 million and a median of -$1.2 million in 2024 define the central range for EBITDA.
- Biggest five-year swings in EBITDA: skyrocketed 92.46% in 2022 and later tumbled 1620.43% in 2023.
- Year by year, EBITDA stood at -$577489.0 in 2021, then fell by 20.07% to -$693364.0 in 2022, then fell by 12.77% to -$781874.0 in 2023, then plummeted by 262.39% to -$2.8 million in 2024, then increased by 16.16% to -$2.4 million in 2025.
- Business Quant data shows EBITDA for NXL at -$2.4 million in Q4 2025, -$2.3 million in Q3 2025, and -$1.6 million in Q2 2025.